Tuesday 26th September 2017
3:00-4:00pm (UK Time)
Organised by the Benefit-Risk Special Interest Group
Recently, we shared an example of adopting benefit risk methodology to schizophrenia studies (click here for more information). Now we are happy to announce that Eva Katz, the epidemiologist behind this nice case study, will give a webinar about it and there will be the possibility to have a discussion around this and how other areas can benefit from it.
Presenter: Eva Katz
Eva Katz, PhD, MPH, RD is Associate Director of Benefit-Risk and Epidemiology at Janssen Research & Development. In this role Dr. Katz serves as an internal consultant for benefit‐risk methodology and patient‐focused benefit‐risk assessment, guiding clinical teams across therapeutic areas in medication benefit-risk assessment using both qualitative and quantitative methods. As part of the efforts to integrate the patient experience in clinical trials, Dr. Katz has helped integrate patient and physician preference surveys within phase 3 clinical trials. Eva also participates in external task forces on benefit‐risk assessment methods and patient focused drug development. Prior to her role in Benefit-Risk, Dr. Katz was part of the patient reported outcomes team at Janssen where she worked cross‐functionally to develop strategy for development, selection and implementation of Patient‐Reported Outcomes (PROs) in phase 2 and phase 3 clinical trials of pharmaceutical products across therapeutic areas. Dr. Katz received her B.S. in Nutritional Science from Rutgers University, her M.P.H. from the University of California, Berkeley and her doctorate in Nutrition Epidemiology from the Gillings School of Global Public Health, University of North Carolina, Chapel Hill.
Please watch for updates as we are organizing the last pieces.
To access the recording, please visit the Video-on-Demand Library.
This course is aimed at clinical trial statisticians who are new to or with limited experience of machine learning. Attendees will learn about a range of topics in machine learning, including practical sessions in R.
This webinar will explore two different approaches to Correlates of Protection in vaccine development.
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
The event will open with an overview on drug development in women’s health from a clinician perspective. This talk is followed by talks about statistical challenges when planning IVF studies and analysing the menstrual cycles.
This webinar will provide an overview of surrogacy for licensing and reimbursement. In turn, the need of extensions of the SPIRIT and CONSORT statement will be defined and outlined, with case studies to support.
Lea Vaas will present how replacement of concurrent control animals by Virtual Control Groups (VCGs) in systemic toxicity studies may help in contributing to the 3R's principle of animal experimentation: Reduce, Refine, Replace.
We will share a brief overview of what Mobilise D is and why it is an important step stone in the development of digital biomarkers, and how Mobilise D outputs can be relevant for you.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
An introductory course giving an overview of the pharmaceutical industry and the drug development process as a whole, aimed at those with 1-3 years' experience. It comprises of six 2-day sessions covering a range of topics including Research and Development, Toxicology, Data Management and the Role of a CRO, Clinical Trials, Reimbursement, and Marketing.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
We have exciting new opportunities available for Study Statisticians, Support Statisticians and Exploratory Statisticians at various levels.
